Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
GRAL Stock Chart & Stats
$96.70
-$1.19(-6.66%)
At close: 4:00 PM EST
$96.70
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$17.50 - $115.76
Previous CloseN/A
Volume371.20K
Average Volume (3M)707.20K
Market Cap
$3.80B
Enterprise Value$1.30B
Total Cash (Recent Filing)$540.13M
Total Debt (Recent Filing)$58.59M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Feb 19, 2026EPS Estimate
-3.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding38,982,224
10 Day Avg. Volume702,085
30 Day Avg. Volume707,195
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.23
Price to Sales (P/S)4.53
P/FCF Ratio-0.98
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue9.17
Enterprise Value/Gross Profit-19.28
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$105.00Price Target Upside8.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-11.53
Revenue Forecast (FY)$174.00M
Bulls Say, Bears Say
Bulls Say
FinancingA private placement that raised about $325 million in gross proceeds materially strengthened the balance sheet and supports continued commercial expansion.
Market TractionA leadership position in the multi-cancer early detection market and roughly 420,000 commercial tests sold indicate strong commercial traction that underpins revenue growth potential.
Strategic PartnershipsA letter of intent with Samsung C&T to commercialize in key Asian markets, together with broader commercial partnerships, creates clear channels to scale international adoption.
Bears Say
Adoption UncertaintyInherent uncertainties around adoption of novel multi-cancer early detection technology and questions over whether observed sensitivity will meet clinician and regulator expectations could delay broader uptake.
Cash Burn RiskOngoing cash burn remains a material risk that could constrain the company's financial runway if operating trends change or key milestones require additional funding.
Payer Acceptance And CostDeclining effective average selling price combined with the potential for higher downstream imaging costs could weaken reimbursement prospects and limit adoption by public payers such as the NHS.
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $17.50 and its highest was $115.76 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $3.80B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Feb 19, 2026 which is in 32 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Nov 12, 2025. The company reported -$2.46 earnings per share for the quarter, beating the consensus estimate of -$3.365 by $0.905.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Undervalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -3.15.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 38,982,224 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$2.46 in its last earnings report, beating expectations of -$3.365. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.00 (8.58% Upside)
$105.00 (8.58% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 821.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $87.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
455.58%
12-Months-Change
Fundamentals
Return on Equity
-16.83%
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
GRAIL Inc
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reveals robust revenue growth, significant clinical trial successes, and strategic international expansion, supported by a strong financial position. However, the company continues to face financial losses and potential regulatory delays.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$105.00
▲(8.58% Upside)
Technical Analysis
Ownership Overview
21.22% Insiders
12.84% Mutual Funds
0.33% Other Institutional Investors
52.44% Public Companies and Individual Investors